company background image
PTCT logo

PTC Therapeutics NasdaqGS:PTCT Stock Report

Last Price

US$29.01

Market Cap

US$2.2b

7D

-5.5%

1Y

-40.2%

Updated

18 Mar, 2024

Data

Company Financials +

PTC Therapeutics, Inc.

NasdaqGS:PTCT Stock Report

Market Cap: US$2.2b

PTCT Stock Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally.

PTCT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance0/6
Financial Health1/6
Dividends0/6

PTC Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PTC Therapeutics
Historical stock prices
Current Share PriceUS$29.01
52 Week HighUS$59.84
52 Week LowUS$17.53
Beta0.66
1 Month Change11.96%
3 Month Change5.11%
1 Year Change-40.17%
3 Year Change-49.12%
5 Year Change-22.70%
Change since IPO75.92%

Recent News & Updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03
PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

Recent updates

PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Mar 03
PTC Therapeutics, Inc. (NASDAQ:PTCT) Surges 27% Yet Its Low P/S Is No Reason For Excitement

PTC Therapeutics: Already Generates Revenues, But Lots Of Outstanding Options

Feb 11

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Jun 23
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

May 18
Benign Growth For PTC Therapeutics, Inc. (NASDAQ:PTCT) Underpins Its Share Price

An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

Mar 02
An Intrinsic Calculation For PTC Therapeutics, Inc. (NASDAQ:PTCT) Suggests It's 49% Undervalued

PTC pauses enrollment in mid-stage study for Huntington's disease candidate in U.S.

Oct 19

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

Aug 05

PTC Therapeutics gene therapy Upstaza wins approval in EU for ultra-rare neuromuscular disorder

Jul 20

PTC Therapeutics: DMD Trial News Unlikely To Restore Flagging Share Price

Jun 24

Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

May 27
Are PTC Therapeutics, Inc. (NASDAQ:PTCT) Investors Paying Above The Intrinsic Value?

PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

Apr 11

Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?

Feb 09
Is Therapeutics (NASDAQ:PTCT) Using Debt Sensibly?

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate

Dec 27
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Could Be 35% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Therapeutics (NASDAQ:PTCT) Use Debt?

Sep 30
Health Check: How Prudently Does Therapeutics (NASDAQ:PTCT) Use Debt?

Shareholder Returns

PTCTUS BiotechsUS Market
7D-5.5%-2.1%0.5%
1Y-40.2%9.7%29.0%

Return vs Industry: PTCT underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: PTCT underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is PTCT's price volatile compared to industry and market?
PTCT volatility
PTCT Average Weekly Movement7.9%
Biotechs Industry Average Movement11.9%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: PTCT has not had significant price volatility in the past 3 months.

Volatility Over Time: PTCT's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,022Matt Kleinhttps://www.ptcbio.com

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis.

PTC Therapeutics, Inc. Fundamentals Summary

How do PTC Therapeutics's earnings and revenue compare to its market cap?
PTCT fundamental statistics
Market capUS$2.22b
Earnings (TTM)-US$626.60m
Revenue (TTM)US$937.82m

2.4x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTCT income statement (TTM)
RevenueUS$937.82m
Cost of RevenueUS$732.05m
Gross ProfitUS$205.77m
Other ExpensesUS$832.38m
Earnings-US$626.60m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-8.18
Gross Margin21.94%
Net Profit Margin-66.81%
Debt/Equity Ratio-256.3%

How did PTCT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.